Orbit Discovery is heading to Biotech Showcase at JPM 2026, where we’ll be highlighting how functional screening is transforming early peptide discovery.
Orbit CEO, Neil Butt, will be there to explain how Orbit's microfluidic platform enables:
• Direct selection of functional agonists/antagonists, not just binders
• High-throughput screening of millions of peptides in physiologically relevant assays
• Rapid identification of true biological hits for GPCRs, transporters and other complex targets
If you’re exploring functional data early to de-risk your programme, let’s connect in San Francisco.